Nat Rev Dis Primers 12 , 5 (2026)
Use in active lifestyles remains investigational because BPC-157 lacks regulatory approval for clinical application in many regions, and current evidence is largely limited to laboratory and animal studies rather than confirmed human outcomes
As of August 3, 2026, retatrutide remained investigational and was not approved by the FDA
True symptom management requires a holistic approach that includes rigorous pacing to avoid post-exertional malaise, detailed symptom tracking to identify specific triggers, nervous system regulation techniques, and ongoing medical care from providers who truly understand post-viral syndromes
To view a copy of this license, visit About this article Cite this article Chen, Y., Singh, S., Matsumoto, A
Khavinson VK, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B